Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
- 28 February 1995
- Vol. 45 (2) , 275-281
- https://doi.org/10.1016/0090-4295(95)80018-2
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)Acta Endocrinologica, 1994
- Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerThe Prostate, 1994
- Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancerBiomedicine & Pharmacotherapy, 1992
- Spinal Cord Compression from Epidural MetastasesNew England Journal of Medicine, 1992
- Hormonal Therapy of Prostatic CarcinomaCancer, 1990
- Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate CancerJournal of Urology, 1990
- New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analoguesInternational Journal of Peptide and Protein Research, 1988
- Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.Proceedings of the National Academy of Sciences, 1988
- Effectiveness of ultrasound in the preoperative evaluation of patients with prostatismThe Prostate, 1988
- Treatment of Advanced Prostatic CancerUrologic Clinics of North America, 1987